Cardio-oncology & otherCohort study
Incidence of Major Adverse Cardiovascular Events (MACE) in Patients Treated With Chimeric Antigen Receptor T (CAR-T) Cell Therapy
- Prospective observational study
- Median follow-up 487 days (Q1-Q3: 258-622 days)
Authors' conclusion
There were few cardiac effects associated with contemporary CAR-T cell therapy.
Study context
- Population
- Adults treated with CAR-T cell therapy
- Participants
- 44 adults
- Outcome
- MACE:
- CV death
- Symptomatic HF
- ACS
- Ischemic stroke
- De novo cardiac arrhythmia
- Follow-up
- 12 months
Main finding
As reported in the abstract
MACE · within 1 year
Patients with MACE (HFpEF and AF), 6 and 7 days after CAR-T infusion
2
Observational data: associations, not effects.
Further findings
CRS
- CRS episodes
- 24
- Patients with CRS
- 23 (52%)
- Grade 1 / grade 2 / grade 3
- 13 / 10 / 1
- Median time to CRS
- 4 days
Echocardiography
- No change in LVEF
- Modest decrease in global longitudinal strain
Original publication
Incidence of MACE in Patients Treated With CAR-T Cell Therapy. JACC CardioOncol. Published 10 October 2023. doi:10.1016/j.jaccao.2023.07.009
Summarised from the published abstract; every number is checked against it